Code Biotherapeutics
Biotechnology, 2801 Sterling Dr, Hatfield, Pennsylvania, 19440, United States, 11-50 Employees
Phone Number: 12*********
Who is CODE BIOTHERAPEUTICS
Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver p...
Read More
-
Headquarters: 2801 Sterling Dr, Hatfield, Pennsylvania, 19440, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Mary Sphar
Email
Phone
Industry: Biotechnology
SIC Code: 8733
|
NAICS Code: 62 |
Show More
Does something look wrong? Fix it. | View contact records from CODE BIOTHERAPEUTICS
Code Biotherapeutics Org Chart and Mapping
Similar Companies to Code Biotherapeutics
Ambagon Therapeutics
-
11-50
-
$ 5 Million to 10 Million
Capstan Therapeutics
-
51-200
-
$ 1 Million to 5 Million
Chroma Medicine
-
51-200
-
$ 25 Million to 50 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Code Biotherapeutics
Answer: Code Biotherapeutics's headquarters are located at 2801 Sterling Dr, Hatfield, Pennsylvania, 19440, United States
Answer: Code Biotherapeutics's phone number is 12*********
Answer: Code Biotherapeutics's official website is https://codebiotx.com
Answer: Code Biotherapeutics's revenue is $1 Million to $5 Million
Answer: Code Biotherapeutics's SIC: 8733
Answer: Code Biotherapeutics's NAICS: 62
Answer: Code Biotherapeutics has 11-50 employees
Answer: Code Biotherapeutics is in Biotechnology
Answer: Code Biotherapeutics top competitors include: Ambagon Therapeutics , Capstan Therapeutics , Chroma Medicine
Answer: Code Biotherapeutics contact info: Phone number: 12********* Website: https://codebiotx.com
Answer: Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity. The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchennes Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Code Biotherapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month